itamin D and its metabolites can be described as a group of secosteroid hormones derived primarily from dermal synthesis after ultraviolet B radiation exposure (sunlight) and also from the diet. Cholecalciferol (vitamin D 3 ), resulting from both skin exposure to ultraviolet B and in limited amounts from dairy products, oily fish, and meat, is considered to be the major contributor to vitamin D concentration (13), whereas ergocalciferol (vitamin D 2 ) is exclusively derived from the diet of irradiated plants and mushrooms and appears to have less biological significance. In the past decade, the understanding of the biological effects of vitamin D has grown exponentially because of the development of the vitamin D knockout mouse (21) and high throughput gene microarray techniques (2). Vitamin D
V itamin D and its metabolites can be described as a group of secosteroid hormones derived primarily from dermal synthesis after ultraviolet B radiation exposure (sunlight) and also from the diet. Cholecalciferol (vitamin D 3 ), resulting from both skin exposure to ultraviolet B and in limited amounts from dairy products, oily fish, and meat, is considered to be the major contributor to vitamin D concentration (13) , whereas ergocalciferol (vitamin D 2 ) is exclusively derived from the diet of irradiated plants and mushrooms and appears to have less biological significance.
After the photosynthetic conversion of 7-dehydrocholesterol to pre-vitamin D 3 and subsequently vitamin D 3 (or cholecalciferol, 14) or after dietary intake, vitamin D is transported in the circulation to the liver bound to the vitamin D-binding protein (DBP), where it is hydroxylated at C-25 by the cytochrome P450 enzyme CYP27A1 (25-hydroxylase) to form 25-hydroxyvitamin D (25[OH]D or calcidiol). This metabolite is then carried, again by DBP, to the kidney where at the proximal renal tubule it is hydroxylated by CYP27B1 (1>-hydroxylase) at C-1> to form the biologically active metabolite 1,25-dihydroxyvitamin D 3 (1, 25 [OH] 2 D or calcitriol) (1) . The active compound 1, 25 [OH] 2 D has long been known as a potent modulator of mineral homeostasis via the transactivation of genes related to the maintenance of calcium and phosphate homeostasis. This biological activity is achieved through interaction of 1, 25 [OH] 2 D 3 with its receptor, the vitamin D receptor (VDR), which heterodimerizes with retinoid X receptor to form a transcriptional complex that can bind to vitamin D response elements in the promoter of vitamin D-regulated genes (11) .
In the past decade, the understanding of the biological effects of vitamin D has grown exponentially because of the development of the vitamin D knockout mouse (21) and high throughput gene microarray techniques (2) . Vitamin D is now understood to be not only an important regulator of mineral homeostasis but may be influential in cell proliferation and differentiation (20) , innate and acquired immunity (12) , and muscle development and repair (25, 26) and in the prevention of psychological diseases such as Alzheimer"s. This is particularly pertinent given the growing understanding that low vitamin D concentrations (G30 nmolIL j1 ) are highly prevalent worldwide in general (33) as well as athletic populations (3, 23) . Despite a rich research base characterizing the biological importance of vitamin D, the regulation of the vitamin D endocrine system is less well understood. Practically, this is an important consideration given that some authors advocate high doses of vitamin D be administered to individuals with osteomalacia/rickets caused by severe vitamin D deficiency (defined G 12.5 nmolIL j1 ) to ameliorate symptoms (14, 18) . In the context of professional sport, it is commonplace to supplement entire teams with a blanket approach to vitamin D supplementation, often without basal concentrations being assessed, and with a target concentration of 9100 nmolIL j1 . Perhaps even more concerning is that the sports teams have access to vitamin D in single capsule at doses up to 50,000 IU (1250 Kg), making single dose weekly supplementation with mega doses practically very simple, and without definitive guidelines for supplementation, this could result in more harm than benefit. Such practice is in discord with recommendations set by the European Food Safety Authority, whom advise a safe daily upper limit of 4000 IUId j1 (8) , in line with advice portrayed by the U.S. Institute of Medicine (IoM) guidelines for vitamin D intake (32) . Notably, the U.S. IoM also state a no adverse effect limit of 10,000 IUId
j1
. Evidence does not exist to appropriately define the effect that high-dose blanket supplementation protocols, commonly used in elite sport, have upon the negative regulators of the vitamin D endocrine system, notably 24,25-hydroxylase (CYP24A1 or 24-hydroxylase), which functions to inactivate both 25 (15) by hydroxylation at C-24. It is important to characterize the response high-dose blanket approaches to avoid potentially detrimental effects of too much supplemental vitamin D and contribute toward the establishment of the most safe and effective vitamin D supplementation schemes for elite athletes.
The current study therefore aimed to characterize the serum responses of the major vitamin D metabolites, 25 
METHODS
Participants. Forty-six elite male elite professional team sport athletes volunteered to participate in the current trial (mean T SD; age = 26 T 3 yr, height = 1.86 T 0.6 m, weight = 101.5 T 11 kg, fat mass = 11.4% T 3%). Participants underwent a medical screening and provided full informed consent before inclusion into the study. Participants were excluded if they were currently taking vitamin D supplements, using sun beds, or injured at the time of the study. Ethical approval was granted by the ethics committee of Liverpool John Moores University (Ethics code 12/SPS/047). The recruitment for the study began in November 2012, and testing commenced in the same month. The study was concluded in April 2013. The study was conducted at latitude 52-N during the winter months to limit sunlight exposure.
Supplementation. Participants were randomly allocated to either 35,000 or 70,000 IUIwk j1 supplemental vitamin D 3 (Maxi Nutrition, UK), herein called moderate and high, respectively. Randomization was achieved with blocking based on baseline serum 25 [OH]D and the use of a random number table to allocate participants into balanced groups. The random allocation sequence was allocated by a member of the research team and known by the rest of the research team at the point of supplement administration. The supplemental doses were chosen based on the fact that they represent widely reported supplement strategies (PubMed literature based search), applied experience of the authors in both clinical and elite sporting settings, and also followed the no adverse effect limit set by the U.S. IoM. Supplements were taken orally as a bolus in capsule form on a weekly basis to increase compliance with the protocol, which was 100% as club staff were present during the weekly distribution of supplementation and monitored the ingestion of capsules to track compliance. Supplementation continued for 12 wk at which point supplementation was ceased to monitor the response of vitamin D metabolites to withdrawal. Participants were blinded to the supplement they were receiving. Forty-two players completed the trial, whereas four dropped out or were excluded for the following reasons: one player did not tolerate venipuncture, one player would not comply with the supplementation protocol, and two players used sun beds during the trial. The vitamin D supplements were batch screened by chromatography and mass spectrometry for contaminants and confirmation of vitamin D content stated on the label. Screening was performed in accordance with ISO standard 17025. Sunlight exposure was minimal during the trial because of the latitude at which the players were based. Participants traveled for a 2-d match fixture to a foreign climate at latitude 43-N, in December during a period of significant cloud cover. Thus, players were exposed to minimal amounts of sunlight during the study period, although no direct measurement of UV exposure was taken.
Blood sampling. Blood samples were drawn before supplementation (basal and then at 6, 12, and 18 (withdrawal) wk from the start of supplementation. Blood was obtained from the antecubital vein into two serum separator tubes and two K 2 EDTA tubes (Becton; Dickinson and Co., Oxford, UK). Samples were then separated to isolate serum/plasma via centrifugation at 1500 RCF for 15 min at 4-C. Serum/plasma was extracted and stored at j80-C until required for analysis. All samples were collected in the medical room of a professional sports club.
Analysis ] in isopropanol-water 50:50 (v/v) was added to 100 KL of human serum samples, calibration standards, and QC to displace binding proteins. After mixing, the samples were loaded onto supported liquid extraction (SLE+) plates (Biotage, Uppsala, Sweden), which were eluted with 1.5 mL of n-heptane. The extraction procedure was performed by Extrahera positive pressure automation system (Biotage). Eluents were dried under nitrogen, followed by reconstitution with 50 KL 4-phenyl-1,2,4-triazoline-3,5-dione (Sigma-Aldrich, Dorset, UK). After a 30-min incubation period at room temperature, 50 KL of water was added to stop the reaction. Twenty microliters of the derivatized extracts was injected into LC-MS/MS. The separation of vitamin D metabolites was achieved using core-shell C18 2. D-linked biotin was added the next day, followed by horseradish peroxidase labeled avidin to selectively bind to biotin complex. After a wash step, color was developed using a chromogenic substrate (3, 3 ¶, 5, 5 ¶-tetramethylbenzidine). The absorbance of the stopped reaction mixtures was read in a microtiter plate spectrophotometer (Multiskan Go; Thermo Scientific, Finland) at wavelength of 450 nm.
Intact PTH in K 2 EDTA plasma samples were determined by electrochemiluminescence immunoassay performed using Roche e601 analyzer (Mannheim, Germany). Two labeled monoclonal antibodies were used to react with the N-terminal fragment (1-37) and the C-terminal fragment (38-84) of PTH, forming a sandwich complex. The antibody complex was magnetically captured and washed to remove unbound substances. A voltage was applied to induce chemiluminescent emission, which was measured by a photomultiplier.
Assay validation. A summary of assay characteristics is described in Supplementary Digital Content 3 (A table highlighting the assay characteristics for each parameter measured, http://links.lww.com/MSS/A784). Linearity of the methods was evaluated by analyzing stock standards made up from reference calibration solutions spiked into human sera. Standard curve was constructed by plotting the analyte response against the concentration of their respective standards. Calibration curves were accepted as linear if the weighted linear regression produced a correlation coefficient (r 2 ) value of 90.999. The intra-and interassay imprecision of the methods was assessed by running QC materials 10 times within a single run and separately over a 3-month period. Assays were deemed acceptable when the QC results fall within T2 SD from the mean value. The lower limit of quantification was determined by the lowest concentration quantifiable with a precision CV of 20% for 12 replicates and a minimum peak signal-to-noise ratio of 10:1 (16). Assay recovery was determined by analyzing samples containing a fixed amount of the analyte and by calculating the percentage of the measured value against the sum of endogenous value plus spiking concentration.
Statistical analyses. Comparisons of basal total serum 25[OH]D concentration for the two dose groups were made using an independent t-test. The effects of vitamin D dose and time on all repeated-measures variables was determined using linear mixed modeling. Time (basal, weeks 6, 12, and 18) and dose (moderate and high) were modeled as fixed effects and participants as a random effect, with time being modeled as a continuous variable where linear or quadratic responses were observed. The covariance structure that minimized the Hurvich and Tsai"s criterion (Corrected Akaike Information Criterion) value was used for the final fitted model for each metabolite. Where significant main or interaction effects were observed, post hoc pairwise comparisons were made with Sidak adjusted P values. All statistical procedures were conducted using the Statistical Package for the Social Sciences for Windows (version 22; IBM, Armonk, NY), and a twotailed statistical significance was accepted at the P G 0.05 level. Descriptive statistics are displayed as means T SD. 
RESULTS
Of the 42 participants that were enrolled onto the trial, 40 were tested for all primary outcome measures. This was due to player commitment to international duty. However, no participants presented with adverse side effects to supplementation during the trial, and thus no participant was withdrawn. Basal (pretreatment) total serum 25[OH]D concentrations were 86 T 20 and 85 T 10 nmolIL j1 for high and moderate treatment groups, respectively (Fig. 1) . These concentrations were not significantly different between groups (t = 0.20, P = 0.84).
Total serum 25 [OH]D displayed a significant interaction effect (F = 4.30, P = 0.008) between dose and time. The exploration of this interaction identified that both groups showed significantly elevated 25 [OH]D concentrations at weeks 6 (moderate = 108 T 22 nmolIL j1 and high = 122 T 25 nmolIL j1 ) and 12 (moderate = 163 T 47 nmolIL j1 and high = 188 T 66 nmolIL j1 ). However, upon supplementation withdrawal, the moderate treatment group demonstrated a return to 25 [OH]D concentrations comparable with basal by week 18 (P = 0.178) whereas the high treatment did not (P = 0.007; Fig. 2A) .
Concentrations of the bioactive metabolite 1>, 25 [OH] 2 D 3 demonstrated a significant main effect for time (F = 6.13, P = 0.001). In the moderate treatment group, peak concentrations occurred at week 6 (141 T 58 pmolIL ). Both groups showed significant increases in this metabolite by week 6 (moderate, P = 0.011; high, P = 0.000), which continued to increase between weeks 6 and 12. A significant interaction effect was also detected as the high treatment group displayed markedly higher peak 24 showed a significant main effect for time (F = 3.39, P = 0.023) but no group main effect with ratios for both supplemental treatments decreasing over the duration of the study, reaching significance by week 12 (P = 0.039) and increasing toward pretreatment values at week 18 (Fig. 3A) . The ratio of showed an inverse relationship at week 6. However, by week 12, both treatment groups showed a significantly lower ratio of 1>, 25 [OH] 2 D 3 :24,25[OH]D (P = 0.005) that was maintained at week 18 after supplementation withdrawal (P = 0.003; Fig. 3C ).
DISCUSSION
The current investigation sought to define the serum responses of the major vitamin D metabolites in a professional athletic cohort to establish the efficacy of a blanket supplementation approach using two commonly used and commercially available doses of vitamin D 3 . (27) and is underpinned by the understanding that DNA-binding sequences exist in the PTH gene (6) VDR as a ''blocking molecule'' binding to the VDR These findings may explain reported observations of deterioration in skeletal muscle function, increased risk of falls, and increased fracture risk in individuals supplemented with extreme dose vitamin D 3 to correct for severe vitamin D deficiency. As an example, in a large-scale trial (n = 2256), women Q70 yr old were randomized to either 500,000 IU of vitamin D 3 or placebo. The women randomized to the supplemental vitamin D 3 experienced significantly more falls than the placebo group in the year after dosing of which the falls ratio was greatest in the first month after the one of 500,000 IU dose (29) . Furthermore, in a retrospective observational cohort study, very low (G10 nmolIL The current trial also had limitations that are important to consider for the design of future work. First, although one of our goals was to use a real-world blanket supplementation approach, we acknowledge that the same protocol used in other athletic cohorts with different body composition, genotype, and lower basal serum 25 [OH]D concentrations may yield different results. Determining the response of the vitamin D metabolites to a similar protocol as we have used here across wider athletic cohorts will allow more conclusive recommendations to be made on dosing concentration and frequency. Indeed, we have previously shown that basal 25 [OH]D concentrations vary across athletes from different professional sports (3) . This assumption is also true for female cohorts, and as such, we appreciate that our findings cannot be conclusively extended to the female athletic population. Regarding genotype, genotypic variation in the DBP influences the response to exogenous vitamin D (9) , and little is known of the variation in genes encoding other vitamin D metabolizing enzymes such as CY24A1 and CYP24B1. We did not perform genotyping, and in light of recent evidence, we fully support genotype-phenotype studies in the context of vitamin D in future. Combining a genotyping approach with vitamin D metabolite ratio data, the latter as we have performed in this study, will offer a great advancement in the understanding of how genotype and supplementation interact and how this can be managed. We also did not measure serum or urinary calcium concentrations, which are markers of vitamin D toxicity and also regulate the PTH response. Measuring Ca 2+ excretion would add another aspect to our findings; however, we do maintain that the observed increases in 24, 25 3 . Further studies will be required to determine whether the relationship we have observed is seen with higher and lower doses of vitamin D.
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